AtriCure Inc. (NASDAQ:ATRC) is scheduled to be announcing its earnings results after the market closes on Wednesday, October 25th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter. AtriCure has set its FY17 guidance at $(1.04)-(0.94) EPS.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, July 27th. The medical device company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. AtriCure had a negative net margin of 15.22% and a negative return on equity of 17.13%. The firm had revenue of $45.23 million during the quarter, compared to the consensus estimate of $44.15 million. During the same quarter in the prior year, the firm earned ($0.26) EPS. AtriCure’s revenue for the quarter was up 14.0% on a year-over-year basis. On average, analysts expect AtriCure to post $-0.95 EPS for the current fiscal year and $-0.71 EPS for the next fiscal year.

Shares of AtriCure Inc. (NASDAQ:ATRC) opened at 22.46 on Wednesday. The company has a 50-day moving average of $21.85 and a 200 day moving average of $21.95. The stock’s market cap is $771.14 million. AtriCure Inc. has a 52-week low of $14.78 and a 52-week high of $25.18.

In other news, Director Elizabeth D. Krell sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $22.40, for a total transaction of $224,000.00. Following the sale, the director now owns 29,967 shares of the company’s stock, valued at $671,260.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 10.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “AtriCure Inc. (ATRC) Set to Announce Quarterly Earnings on Wednesday” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at

Several equities research analysts recently commented on ATRC shares. Zacks Investment Research cut AtriCure from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Needham & Company LLC restated a “buy” rating and issued a $26.00 target price (up from $25.00) on shares of AtriCure in a report on Friday, July 28th. Canaccord Genuity restated a “buy” rating and issued a $28.00 target price on shares of AtriCure in a report on Monday, October 9th. BidaskClub lowered AtriCure from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $25.00 price target on shares of AtriCure in a report on Sunday, July 30th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. AtriCure has a consensus rating of “Buy” and a consensus target price of $25.83.

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Earnings History for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with's FREE daily email newsletter.